SCHEMBL6041098

SCHEMBL6041098

COc1ccccc1C(=O)Nc1ccc(C)c(Nc2nccc(N3C=CC=NC3)n2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.61
PDGFRB P09619 4/20 0.61
BCR P11274 4/20 0.61
PDGFRA P16234 4/20 0.61
PRKCA P17252 4/20 0.61
BMX P51813 2/20 0.48
LCK P06239 2/20 0.48
EGFR P00533 2/20 0.46
KDR P35968 1/20 0.46
MAPK14 Q16539 1/20 0.46
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KCNK3 O14649 2/20 0.43
KCNK9 Q9NPC2 2/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6041152 0.88 ABL1 (0.59) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL6041097 0.85 BMX (0.46) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL6041103 0.82 ABL1 (0.61) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL6041094 0.79 ABL1 (0.45) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL4901273 0.78 ABL1 (0.76) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL4896195 0.77 ABL1 (0.84) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL4903174 0.76 ABL1 (0.79) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL6041086 0.76 KIT (0.66) ABL1PDGFRBBCRPDGFRALCK
SCHEMBL9666 0.76 PDGFRA (1.00) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL6041148 0.74 ABL1 (0.57) ABL1PDGFRBBCRPDGFRAPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060217404-A1 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) 2006-09-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217404-A1 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases PRNP, PPM1D, PPM1F ABL1 904/4885PDGFRB 2329/4885BCR 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.